Biogen Acquires RayThera for Up to $1 Billion
Biogen has agreed to acquire RayThera, a biotechnology firm specializing in small-molecule therapies for immunology, for up to $1 billion. The deal includes an upfront payment and milestone-based payments tied to clinical and regulatory achievements. This acquisition is expected to bolster Biogen's pipeline with anti-inflammatory candidates.
Tickers: $BIIB